
Roche unveils new Alzheimer’s drug and diagnostic data at CTAD 2026, advancing treatment and early detection.
Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start...





